Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
/CNW/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major...
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments
/CNW/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...
Cardiff Oncology Reports Promising Initial Results from Phase 2 CRDF-004 Trial of Onvansertib in RAS-Mutated mCRC
Cardiff Oncology's Phase 2 trial shows onvansertib combined with SoC yields 64% ORR in RAS-mut mCRC patients.Quiver AI SummaryCardiff Oncology, Inc. announced positive preliminary results from its Phase...